![]()
31
| 1 | 2008
Klinisk Biokemi i Norden
(Fortsætter side 32)
ent on the match between the probe and the sample.
This approach is utilized for genotyping of SNPs (54).
Microarrays
Different microarray platforms are available today
using different types of arrays; spotted cDNA arrays or
oligonucleotide arrays for gene expression analysis and
(55) and mapping arrays for SNPs, linkage analysis,
whole genome association, population genetics, and
chromosomal copy number changes (56). However,
the basic principle which relies on nucleic acid hybridi-
zation between labeled targets and large arrayed sets of
gene fragments on solid support, is the same for most
microarrays (57;58). One of the challenges is to decide
an analytical strategy for identification of new genes
or disease mechanisms. One criterion often used is a
twofold difference in expression levels. Appropriate
statistical analysis is needed to analyze such huge
amounts of data. As all array technologies of today
are expensive and the data volume enormous, the
researchers approaching these technology platforms
faces several challenges. Experimental design should
be carefully planned and ideally biostatistics expertise
included from the start. Such expertise will subse-
quently be needed in mining the data. Considerations
in appropriate biobanking of collected specimens will
be necessary. In short preanalytical, analytical and
postanalytical insight into the biology involved, will be
mandatory to obtain reliable results.
Reference List
1. Johnson PJ, Lo YM. Plasma nucleic acids in
the diagnosis and management of malignant
disease. Clin Chem 2002;48:1186-93.
2. Ogawa M. Differentiation and prolif-
eration of hematopoietic stem cells. Blood
1993;81:2844-53.
3. Peltonen L, McKusick VA. Genomics and
medicine. Dissecting human disease in the
postgenomic era. Science 2001;291:1224-9.
4. Chakravarti A. Population genetics--
making sense out of sequence. Nat Genet
1999;21:56-60.
5. Crawford DC, Akey DT, Nickerson DA.
The patterns of natural variation in human
genes. Annu Rev Genomics Hum Genet
2005;6:287-312.
6. Esteller M. Aberrant DNA methylation as
a cancer-inducing mechanism. Annu Rev
Pharmacol Toxicol 2005;45:629-56.
7. von Zglinicki T, Martin-Ruiz CM. Telomeres
as biomarkers for ageing and age-related dis-
eases. Curr Mol Med 2005;5:197-203.
8. Bertina RM, Koeleman BP, Koster T,
Rosendaal FR, Dirven RJ, de Ronde H et al.
Mutation in blood coagulation factor V asso-
ciated with resistance to activated protein C.
Nature 1994;369:64-7.
9. Poort SR, Rosendaal FR, Reitsma PH, Bertina
RM. A common genetic variation in the
3'-untranslated region of the prothrombin
gene is associated with elevated plasma pro-
thrombin levels and an increase in venous
thrombosis. Blood 1996;88:3698-703.
10. Feder JN, Gnirke A, Thomas W, Tsuchihashi
Z, Ruddy DA, Basava A et al. A novel MHC
class I-like gene is mutated in patients with
hereditary haemochromatosis. Nat Genet
1996;13:399-408.
11. Enattah NS, Sahi T, Savilahti E, Terwilliger JD,
Peltonen L, Jarvela I. Identification of a vari-
ant associated with adult-type hypolactasia.
Nat Genet 2002;30:233-7.
12. Allen WL, Johnston PG. Role of genomic
markers in colorectal cancer treatment. J Clin
Oncol 2005;23:4545-52.
13. Miyamoto K, Ushijima T. Diagnostic and
therapeutic applications of epigenetics. Jpn J
Clin Oncol 2005;35:293-301.
14. Maier S, Dahlstroem C, Haefliger C, Plum A,
Piepenbrock C. Identifying DNA methylation
biomarkers of cancer drug response. Am J
Pharmacogenomics 2005;5:223-32.
15. Ingelman-Sundberg M. Pharmacogenetics of
cytochrome P450 and its applications in drug
therapy: the past, present and future. Trends
Pharmacol Sci 2004;25:193-200.
16. Ingelman-Sundberg M. Pharmacogenetics: an
opportunity for a safer andmore efficient phar-
macotherapy. J Intern Med 2001;250:186-200.
17. Wadelius M, Chen LY, Downes K, Ghori
J, Hunt S, Eriksson N et al. Common
VKORC1 and GGCX polymorphisms associ-
